Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
The Japanese government granted special emergency approval for MSD’s antiviral Lagevrio Capsules (molnupiravir) on December 24, making it the country’s first oral treatment for COVID-19. Health Minister Shigeyuki Goto approved the drug immediately after it was given the blessing at…
To read the full story
Related Article
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- MSD Japan Set to Supply 1.6 Million Courses of Lagevrio by September: President
January 26, 2022
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
REGULATORY
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…